TABLE 39A LIST OF PUBLICATIONS REFERRED TO IN THE ...

mortality after kidney transplantation. Clin Infect Dis 2008;46:840-6.
29B.22 Torres-Madriz G et al. Perspectives in the treatment and prophylaxis of cytomegalovirus disease in
solid-organ transplant recipients. Clin Infect Dis 2008;47:702-11.
29B.23 Griffiths P et al. Contemporary management of cytomegalovirus infection in transplant recipients:
guidelines from an IHMF Workshop, 2007. Herpes 2008;15:4-12.
29B.24 Hodson EM et al. Antiviral medications to prevent cytomegalovirus disease and early death in recipients
of solid-organ transplants: a systematic review of randomised controlled trials. Lancet 2005;365:
2105-15.
29B.25 Kalil AC et al. Meta-Analysis: The efficacy of strategies to prevent organ disease by cytomegalovirus
in solid organ transplant recipients. Ann Intern Med 2005;143:870-80.
29B.26 Preiksaitis JK et al. Canadian Society of Transplantation Consensus Workshop on Cytomegalovirus
Management in Solid Ogan Transplantation. Final report. Am J Transplant 2005;5:218-27.
29B.27 Singh N. Late onset cytomegalovirus disease as a significant complication in solid organ transplant
recipients receiving antiviral prophylaxis: a call to heed the mounting evidence. Clin Infect Dis 2005;
40:704-8.
29B.28 Snydman DR. Counterpoint: prevention of cytomegalovirus (CMV) infection and CMV disease in recipients
of solid organ transplants: the case for prophylaxis. Clin Infect Dis 2005;40:709-12.
29B.29 Mwintshi K et al. Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus
in solid organ transplant recipients. Expert Rev Anti Infect Ther 2007;5:295-304.
29B.30 Small LN et al. Preventing post-organ transplantation cytomegalovirus disease with ganciclovir: a meta-analysis
comparing prophylactic and preemptive therapies. Clin Infect Dis 2006:43:869-80.
29B.31 Meylan PR et al. Preemptive versus prophylactic approaches in the management of cytomegalovirus
disease in solid organ transplant recipients: what we know and what we do not know. Clin Infect Dis
2006;43:881-3.
29B.32 Legendre C et al. Improving outcomes for solid-organ transplant recipients at risk from cyto-megalovirus
infection: late-onset disease and indirect consequences. Clin Infect Dis 2008;46:732-40.
29B.33 van der Heiden PL et al. Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus
DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients.
Bone Marrow Transplant 2006;37:693-8.
29B.34 Ayala E et al. Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic
hematopoietic stem cell transplantation. Bone Marrow Transplant 2006;37:851-6.
29B.35 Allice T et al. Valganciclovir as pre-emptive therapy for cytomegalovirus infection post-allogenic stem
cell transplantation: implications for the emergence of drug-resistant cytomegalovirus. J Antimicrob
Chemother 2009;63:600-8.
29B.36 Busca A et al. Oral valganciclovir as preemptive therapy for cytomegalovirus infection post allogeneic
stemcell transplantation. Transpl Infect Dis 2007;9:102-7.
29B.37 Strasfeld L et al. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients:
current issues and new agents. Expert Rev Anti Infect Ther 2006;4:457-68.
29B.38 Zaia JA. Prevention of cytomegalovirus disease in hematopoietic stem cell transplantation. Clin Infect
Dis 2002;35:999-1004.
29B.39 Meijer E et al. Prevention of cytomegalovirus disease in recipients of allogeneic stem cell transplants.
Clin Microbiol Rev 2003;16:647-57.
29B.40 Li F et al. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart
transplant recipients. Clin Infect Dis 2007;45:439-47.
29B.41 Avery RK. Ganciclovir-resistant cytomegalovirus disease in heart transplant recipients: the dilemma
of donor-positive/recipient-negative serostatus. Clin Infect Dis 2007;45:448-9.
29B.42 Levitsky J et al. A survey of CMV prevention strategies after liver transplantation. Am J Transplant
2008;8:158-61.
29B.43 Egli A et al. Cytomegalovirus-associated chorioretinitis after liver transplantation: case report and review
of the literature. Transpl Infect Dis 2008;10:27-43.
29B.44 Singh N et al. Efficacy of valganciclovir administered as pre-emptive therapy for cytomegalovirus disease
in liver transplant recipients: impact on viral load and late onset cytomegalovirus disease.
Transplantation 2005;79:85-90.
29B.45 Singh N et al. Indirect outcomes associated with cytomegalovirus (opportunistic infections, hepatitis C
virus sequelae and mortality) in liver transplant recipients with the use of pre-emptive therapy for 13
years. Transplantation 2005;79:1428-34.
29B.46 Zamora MR et al. Management of cytomegalovirus infection in lung transplant recipients: evidence
based recommendations. Transplantation 2005;80:157-63.
29B.47 Perrillo RP et al. A Multicenter United States-Canadian trial to assess lamivudine monotherapy before
and after liver transplantation for chronic hepatitis B. Hepatology 2001;33:424-32.
29B.48 Naoumov NV et al. Randomized trial of lamivudine versus hepatitis B immunoglobulin for long-term
prophylaxis of hepatitis B recurrence after liver transplantation. J Hepatol 2001;34:888-94.
29B.49 Coffin CS et al. Management of hepatitis B in liver transplant recipients. J Viral Hepat 2007;14
(suppl. 1):37-44.
29B.50 Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004;24
(suppl. 1):55-62.
29B.51 Gasink LB et al. Hepatitis C virus seropositivity in organ donors and survival in heart transplant recipients.
J Am Med Assoc 2006;296:1843-50.
29B.52 Biggins SW et al. Management of recurrent hepatitis C in liver transplant recipients. Infect Dis Clin
North Am 2006;20:155-74.
29B.53 Miller GG et al. Herpes simplex and varicella zoster viruses: forgotten but not gone. Am J Transplant
2007;7:741-7.
29B.54 Erard V et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation:
impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007;
196:266-70.
29B.55 Erard V et al. Use of long-term suppressive acyclovir after hematopoietic stem-cell transplantation:
impact on herpes simplex virus (HSV) disease and drug-resistant HSV disease. J Infect Dis 2007;
193:266-70.